ICER Draft Evidence Report on oral semaglutide mixed

12 September 2019

The Institute for Clinical and Economic Review (ICER) on Wednesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Danish diabetes care giant Novo Nordisk’s (NOV: N) oral semaglutide and other treatments for type 2 diabetes mellitus.

The US medicines cost-effectiveness organization noted that that, while the semaglutide pill did a better job of preventing cardiovascular complications, itonly offers an “incremental benefit” in preventing adverse cardiac events when compared with products such as Jardiance (empagliflozin) from Eli Lilly (NYSE: LLY) and Boehringer Ingelheim.

Based on the current clinical evidence, with limited follow-up, and without knowing the eventual price for oral semaglutide, the ICER said it is unable to draw conclusions on its cost effectiveness with any certainty. The ultimate value of oral semaglutide will be determined by the price that is set by the manufacturer and its long-term effectiveness, it stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK